Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management.
about
Protective mechanisms of Cucumis sativus in diabetes-related modelsof oxidative stress and carbonyl stressHypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver diseaseObesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines.Independent tissue contributors to obesity-associated insulin resistance.Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetesThe influence of dietary fat on liver fat accumulation.From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitationsPractical approach to non-alcoholic fatty liver disease in patients with diabetes.Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic ratsPartial replacement with menhaden oil improves peripheral neuropathy in high-fat-fed low-dose streptozotocin type 2 diabetic ratMisregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity.The role of skeletal muscle in development of nonalcoholic Fatty liver disease.Association of Multiple Biomarkers of Iron Metabolism and Type 2 Diabetes: The EPIC-InterAct Study.Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: is there is a place for obstructive sleep apnea?Metabolic dysfunction following weight cycling in male mice.Association between liver function and metabolic syndrome in Chinese men and women.Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.Characterization of lipid metabolism in a novel immortalized human hepatocyte cell line.Late effects of childhood cancer treatment: severe hypertriglyceridaemia, central obesity, non alcoholic fatty liver disease and diabetes as complications of childhood total body irradiation.Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.Hypolipidemic, Hepatoprotective and Renoprotective Effects of Cydonia Oblonga Mill. Fruit in Streptozotocin-Induced Diabetic Rats.Steatosis in South African women: How much and why?Influence of dietary macronutrients on liver fat accumulation and metabolism.Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice.Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet.Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle.Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study.
P2860
Q28829425-7DB80959-6CCE-4F18-B960-362BFD150D5DQ33573989-431E5E5F-AC92-4509-A8AD-BD03948F5DF8Q33628222-A9D1B49D-D8DA-4368-A648-D069E166878FQ33877805-62139B11-C010-4F4E-9F3F-15D03AE1C3F8Q34205386-A3E53C13-6FFE-4A5F-BADC-90DD413FFB81Q34578071-05C0FC3F-939F-4774-A283-30F2453213D3Q34800989-DAB93432-BB1C-4A47-B1D5-B967A9A55F51Q35561693-EE4EE581-5843-44F3-B834-F7A2EBE6C7FAQ35819533-AF42BAB9-31AE-4C03-9B66-8B68E9DCBCB3Q36228773-5E648025-C0F6-4402-8305-EE0EC22BCEC8Q36478196-B891CB01-4B9B-45FE-BBD2-99BE1B7BF078Q37121610-FB137B7E-FBE1-463D-9C41-1FD5D160FD83Q37327008-5B9F30CA-798F-4560-9FDF-6860A7142BEFQ37539722-95DB67DD-509B-42B1-9F7F-A9A34741BE96Q37691397-DAECCB95-71E0-41D3-8C5B-293505D9B2C8Q37710720-B80961DB-4B8A-494E-B1F7-DD486F1746F6Q38097092-4C392F07-954D-4AE2-B507-3E5E65842E31Q38199526-B3E1F8CF-3BE1-4D3B-9C25-B42F7B454CD1Q38236774-9AD29E77-4F96-4A09-BBDD-389171A7235DQ38606360-EE714966-E46B-44A8-8B17-D9D738988B49Q38858403-789DB823-F45C-4987-91DA-F04316033286Q39414950-8A074831-113F-4C71-BAD1-BCF890F05144Q41730826-F47D6802-CB18-4DC4-9011-9BF73DC06B97Q41813630-B200130D-49A6-4AC8-B7F9-423431C471B7Q47551195-94E8C34B-1BBF-468F-AECB-270AD3D4101BQ47744258-E274E648-979C-4A8E-AE6D-9FB8F108F5FEQ50474642-C8C573CA-BBED-4382-92CC-75CE0E744751Q50490456-43EA2D57-0226-4753-AA22-625D82A53047Q53113517-8161C66B-72FA-4429-82BB-8F1D407E5445Q55091484-135B7CFA-14FF-4ACD-9CF3-B7F21DA6FA58
P2860
Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dorothy Hodgkin Lecture 2012: ...... roblem in diabetes management.
@en
type
label
Dorothy Hodgkin Lecture 2012: ...... roblem in diabetes management.
@en
prefLabel
Dorothy Hodgkin Lecture 2012: ...... roblem in diabetes management.
@en
P2860
P1433
P1476
Dorothy Hodgkin Lecture 2012: ...... problem in diabetes management
@en
P2093
P2860
P304
P356
10.1111/J.1464-5491.2012.03732.X
P577
2012-09-01T00:00:00Z